Every 10-Q that Lakeside Holding Limited (LSH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LSH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LSH filings page.
Lakeside Holding Limited reports results for the quarter and nine months ended March 31, 2026, showing rapid revenue growth but ongoing losses and tight liquidity. Revenue from continuing operations reached $5.1 million for the nine months and $1.3 million for the quarter, driven by pharmaceutical distribution.
The company recorded a nine‑month net loss of $2.8 million, including a $3.5 million loss from continuing operations partly offset by a $2.6 million gain on the sale of discontinued subsidiary ABL Chicago. Cash fell to $1.3 million, while a loan receivable from a third party increased to $8.3 million net.
Management discloses that recurring losses, negative operating cash flow and reliance on external financing raise substantial doubt about Lakeside’s ability to continue as a going concern and plans to rely on loans, notes and additional equity financing to support operations and acquisition projects.
Lakeside Holding Limited reported strong revenue growth but continued losses for the six months ended December 31, 2025. Total revenue rose to $13,112,522 from $7,677,143, driven by cross-border airfreight and new pharmaceutical product distribution.
Despite higher sales, the company posted a net loss of $2,940,897, compared with a loss of $3,282,227 a year earlier. Loss per share improved to $0.17 from $0.44, mainly because the share count increased.
Cash declined to $1,641,438 from $4,956,060 as operations used $4,469,978 of cash and investing activities used $7,145,990, partly to fund a loan receivable from a third party of $7,148,622. An expected credit loss allowance of $288,000 was recorded on this loan.
The company raised equity through private placements, stock issued for consulting services, and convertible note exercises, increasing common shares outstanding to 34,427,559 and lifting total equity to $12,178,691. Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing ongoing losses and reliance on external financing.
Lakeside Holding Limited reports results for the three months ended September 30, 2025, with total revenue of $6,099,889, up from $4,081,554 a year earlier, driven by growth in cross-border airfreight and new pharmaceutical distribution sales. Gross profit more than doubled to $1,108,767, but operating expenses rose to $2,380,391, leaving a loss from operations of $1,271,624.
Net loss was $1,357,216, similar to the prior period’s $1,335,407, and basic and diluted loss per share improved to $0.09 from $0.18 due to a larger share count. Cash used in operating activities increased to $4,016,518, while financing inflows of $3,672,316, including a $3,000,000 private placement and new loans, helped support liquidity.
Total assets rose to $18,635,189 and equity to $6,954,330 as of September 30, 2025, reflecting share issuances for consulting services, conversion of convertible notes, and the private placement. Loans payable increased to $2,419,103, and the company continues to rely on bank and third-party borrowings alongside equity financing to fund expansion and working capital.